【摘要】 目的探讨肺癌患者血清转化生长因子-β1(TGF-β1)的水平变化和临床意义。方法采用酶联免疫吸附试验(ELISA)检测60例肺癌患者及30例健康者血清TGF-β1水平。结果肺癌组血清TGF-β1水平(30.073±13.790)ng/m l明显高于正常对照组(15.787±12.863)ng/m l(P<0.01);小细胞肺癌(SCLC)组血清TGF-β1水平(31.671±15.172)ng/m l与非小细胞肺癌(NSCLC)组的(28.766±12.635)ng/m l比较,差异无显著性(P>0.05);Ⅲ~Ⅳ期肺癌患者血清TGF-β1水平均明显高于Ⅰ~Ⅱ期肺癌患者(P<0.01)。结论肺癌患者血清TGF-β1水平显著高于健康对照组,与肺癌病理类型无关,随TNM分期进展而升高,TGF-β1可能是肺癌的一种血清肿瘤标志物,并可作为病情监测指标。更多还原

【Abstract】 Objective To explore the change in serum transforming growth factor-β1(TGF-β1) level in patients with lung cancer and to analyze its clinical significance.Methods The serum level of TGF-β1 was measured by enzyme-linked immunosorbent assay(ELISA) in 60 patients with lung cancer and 30 healthy control subjects.Results The serum level of TGF-β1 in patients with lung cancer(30.073±13.790 ng/ml) was significantly higher than that in normal subjects(15.787±12.863 ng/ml)(P<0.01).There was no significant difference in serum level of TGF-β1 between small cell lung cancer(SCLC)(31.671±15.172 ng/ml) and non-small cell lung cancer(NSCLC)(28.766±12.635 ng/ml)(P>0.05).The serum level of TGF-β1 was significantly higher in patients with stage Ⅲ-Ⅳ lung cancer compared with that in stageⅠ-Ⅱlung cancer(P<0.01).Conclusion The serum level of TGF-β1 in patients with lung cancer is significantly higher than that in normal subjects.It shows no relation to pathological types.But it raises with the increasing of TNM stages.The serum TGF-β1 may be a serum tumor marker and served as an useful indicator in the assessment of clinical stage.更多还原